Trinity Biotech (TRIB) Gross Profit (2009 - 2024)

Trinity Biotech has disclosed Gross Profit across 16 years of filings, most recently posting $4.9 million for Q4 2024.

• Gross Profit for Q4 2024 came in at $4.9 million, up 6.79% year-over-year; the trailing twelve-month figure through Dec 2024 was $21.4 million (up 10.24% YoY), and the FY2025 annual result was $16.9 million, down 21.24% from the prior year.
• Gross Profit came in at $4.9 million for Q4 2024 at Trinity Biotech, down from $5.3 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $16.8 million in Q3 2020 to a low of $329000.0 in Q3 2022.
• The 5-year median for Gross Profit is $5.7 million (2022), against an average of $7.2 million.
• Across the five-year window, Gross Profit tumbled 96.3% in 2022 and jumped 1200.91% in 2023, its largest moves.
• Trinity Biotech's Gross Profit stood at $15.7 million in 2020, then sank by 53.77% to $7.2 million in 2021, then decreased by 25.75% to $5.4 million in 2022, then retreated by 15.03% to $4.6 million in 2023, then gained by 6.79% to $4.9 million in 2024.
• The last three Gross Profit figures came in at $4.9 million (Q4 2024), $5.3 million (Q3 2024), and $5.7 million (Q2 2024), per Business Quant data.